Payment overview · 2025
General Payments
$481.67
15 reported records · 8 companies
Healthcare provider profile · identity verified
Daniel H. Pham, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OKLAHOMA CITY, OK · NPI 1114123114
Verified facts
What the public records show
CMS Open Payments records show Daniel H. Pham, M.D. received $481.67 in general payments during 2025 across 15 reported records.
Pulmonx Corporation accounted for 36.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Mounjaro, Shingrix, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $177.22 | 36.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $76.93 | 16.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.75 | 13.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.77 | 11.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.84 | 8.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.14 | 5.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.34 | 4.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.68 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $481.67 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $177.22 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $177.22 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $177.22 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $177.22 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $76.93 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $43.57 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.84 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.84 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.14 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.61 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 89 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 79 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 107 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
89 | 88 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
107 | 82 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 479 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 92 |
| Gabapentin | Gabapentin | 231 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 50 |
| Lisinopril | Lisinopril | 141 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 56 |
| Losartan Potassium | Losartan Potassium | 125 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 73 |
| Alendronate Sodium | Alendronate Sodium | 116 | 44 |
| Metformin Hcl | Metformin Hcl | 111 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 39 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 107 | 82 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 100 | 95 |
| Omeprazole | Omeprazole | 99 | 37 |
| Potassium Chloride | Potassium Chloride | 93 | 34 |
| Metformin Hcl Er | Metformin Hcl | 90 | 40 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 89 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 88 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 37 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 82 | 25 |
| Jardiance | Empagliflozin | 79 | 29 |
| Methylprednisolone | Methylprednisolone | 72 | 56 |
| Ozempic | Semaglutide | 72 | 17 |
| Allopurinol | Allopurinol | 69 | 22 |
| Trazodone Hcl | Trazodone Hcl | 68 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 22 |
| Celecoxib | Celecoxib | 63 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 23 |
| Azithromycin | Azithromycin | 62 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 21 |
| Famotidine | Famotidine | 61 | 27 |
| Naproxen | Naproxen | 61 | 20 |
| Montelukast Sodium | Montelukast Sodium | 60 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 12 |
| Eliquis | Apixaban | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 15 |
| Furosemide | Furosemide | 46 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 16 |
| Farxiga | Dapagliflozin Propanediol | 42 | 16 |
| Januvia | Sitagliptin Phosphate | 42 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 14 |
| Ibuprofen | Ibuprofen | 41 | 23 |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 31 |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 14 |
| Ezetimibe | Ezetimibe | 35 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Meloxicam | Meloxicam | 33 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | 11 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Carvedilol | Carvedilol | 26 | 12 |
| Finasteride | Finasteride | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Baclofen | Baclofen | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Prolia | Denosumab | 18 | 14 |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nystatin | Nystatin | 17 | 13 |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $481.67 · 15 records | Pulmonx Corporation | AIRSUPRA, AREXVY, CHARTIS CATHETER, Cologuard Collection Kit, Dexcom G6 Transmitter, INSPIRE, JARDIANCE, MOUNJARO, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error